Related references
Note: Only part of the references are listed.Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making
Marc Debled et al.
AMERICAN JOURNAL OF SURGERY (2014)
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
Eva Ciruelos et al.
BREAST (2014)
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery
Robert Carpenter et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Estrogen Receptor Mutations in Breast Cancer-New Focus on an Old Target
Corrinne V. Segal et al.
CLINICAL CANCER RESEARCH (2014)
Sox2 promotes tamoxifen resistance in breast cancer cells
Marco Piva et al.
EMBO MOLECULAR MEDICINE (2014)
Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data
Arief Gusnanto et al.
BIOINFORMATICS (2012)
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
Irene Kuter et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
John F. R. Robertson et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy
Norasate Samarnthai et al.
BREAST JOURNAL (2012)
ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer
Maria Kalyuga et al.
PLOS BIOLOGY (2012)
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
A. DeCensi et al.
ANNALS OF ONCOLOGY (2011)
Is the Ki-67 labelling index ready for clinical use?
W. Jonat et al.
ANNALS OF ONCOLOGY (2011)
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer
Suleiman Massarweh et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Nucleic Acid Quality Preservation by an Alcohol-based Fixative Comparison With Frozen Tumors in a Routine Pathology Setting
Isabelle Hostein et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Y. H. Chia et al.
BRITISH JOURNAL OF CANCER (2010)
Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens
Henry M. Wood et al.
NUCLEIC ACIDS RESEARCH (2010)
Neoadjuvant endocrine treatment in primary breast cancer - Review of literature
J. Mathew et al.
BREAST (2009)
Increase in response rate by prolonged treatment with neoadjuvant letrozole
J. Michael Dixon et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Frederik Holst et al.
NATURE GENETICS (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
M Dowsett et al.
CLINICAL CANCER RESEARCH (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases:: combined results from two multicentre trials
L Mauriac et al.
EUROPEAN JOURNAL OF CANCER (2003)
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women
L Mauriac et al.
ANNALS OF ONCOLOGY (2002)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
